miR-122在非酒精性脂肪肝病患者血清中的表达及其临床意义

Abstract
Figure/Table
References
Related Citation (8)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the expression levels of serum microRNA-122 (miR-122) in non-alcoholic fatty liver disease (NAFLD) patients, and its clinical significance. Methods Patients with normal liver, hyperlipidemia, non-alcoholic simply fatty liver(NAFL), non-alcoholic steatohepatitis(NASH)were included in this study. Blood samples of the patients were collected for analysis. Real time quantitative PCR technique was used to measure the expression level of serum miR-122. Results The expression levels of serum miR-122 was 5.94±1.21(2^-△△Ct), 5.99±1.03(2^-△△Ct), 8.67±0.72(2^-△△Ct)and 10.55±0.83(2^-△△Ct), respectively. The difference in the expression level between normal liver and hyperlipidemia patients was not statistically significant. Comparing with normal liver and hyperlipidemia patients, miR-122 presented higher expressions in NAFL patients(P<0.05), especially in NASH patients. Conclusion miR-122 plays an important role in NAFLD development and has early diagnostic value for indicating NAFLD. It may also be a potential therapeutic target in NAFLD with significant clinical value.

Key words： NAFLD fatty acid metabolism early diagnosis miR-122

Received: 17 May 2014

ZTFLH:

R575.5

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Yi
	CHEN Yiyao
	CAI Manni
	WU Huazhi

Cite this article:

CHEN Yi,CHEN Yiyao,CAI Manni等. Expression of miR-122 in nonalcoholic fatty liver disease and its clinical significance[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2015, 26(1): 11-12.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2015/V26/I1/11

[5]	中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南[J].中国肝脏病杂志(电子版), 2010, 2(4):43-48.
[6]	中国成人血脂异常防治指南制定联合委员会. 中国成人血脂异常防治指南[J]. 中华心血管病杂志, 2007, 35(5):390-419.
[1]	Brunt E M. Pathology of nonalcoholic fatty liver disease[J].Nat Rev Gastroenterol Hepatol, 2010, 7:195-203.
[7]	Livak K J, Schmittgen T D.Analysis of relative gene expression data using real-time quantitative PCR and the 2[-Delta Delta C(T)] Method[J].Methods, 2001, 25(4):402-408.
[2]	Jopling C. Liver-specific microRNA-122:biogenesis and function[J].RNA Biol, 2012, 9(2):1-6.
[8]	Bartel D P. MicroRNAs: genomics, biogenesis, mechanism, and function[J]. Cell, 2004, 116:281-297.
[3]	Elmen J, Lindow M, Silahtaroglu A, et al. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver[J].Nucleic Acids Res, 2008, 36(4):1153-1162.
[9]	Ambros V. The functions of animal microRNAs[J].Nature, 2004, 431(7006):350-355.
[10]	Moore K J, Rayner K J, Suárez Y, et al. microRNAs and cholesterolmetabolism[J]. Trends Endocrinol Metab, 2010, 21(12): 699-706.
[4]	Esau C, Davis S, Murray S F, et al. miR -122 regulation of lipid metabolism revealed by in vivo antisense targeting [J].Cell Metab, 2006, 3(2):87-98.
[5]	中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南[J].中国肝脏病杂志(电子版), 2010, 2(4):43-48.
[11]	Fernandez-Hernando C, Suarez Y, Rayner K J, et al. MicroRNAs in lipid metabolism[J]. Curr Opin Lipidol, 2011, 22(2): 86-92.
[6]	中国成人血脂异常防治指南制定联合委员会. 中国成人血脂异常防治指南[J]. 中华心血管病杂志, 2007, 35(5):390-419.
[12]	Gerin I, Clerbaux L A, Haumont O, et al. Expression of miR-33 from an SREBP2 intron inhibits cholesterol export and fatty acid oxidation[J]. J Biol Chem, 2010, 285(44):33652-33661.
[7]	Livak K J, Schmittgen T D.Analysis of relative gene expression data using real-time quantitative PCR and the 2[-Delta Delta C(T)] Method[J].Methods, 2001, 25(4):402-408.
[13]	Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNA in vivo with 'antagomirs'[J]. Nature, 2005, 438(7068):685-689.
[8]	Bartel D P. MicroRNAs: genomics, biogenesis, mechanism, and function[J]. Cell, 2004, 116:281-297.
[9]	Ambros V. The functions of animal microRNAs[J].Nature, 2004, 431(7006):350-355.
[10]	Moore K J, Rayner K J, Suárez Y, et al. microRNAs and cholesterolmetabolism[J]. Trends Endocrinol Metab, 2010, 21(12): 699-706.
[11]	Fernandez-Hernando C, Suarez Y, Rayner K J, et al. MicroRNAs in lipid metabolism[J]. Curr Opin Lipidol, 2011, 22(2): 86-92.
[12]	Gerin I, Clerbaux L A, Haumont O, et al. Expression of miR-33 from an SREBP2 intron inhibits cholesterol export and fatty acid oxidation[J]. J Biol Chem, 2010, 285(44):33652-33661.
[13]	Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNA in vivo with 'antagomirs'[J]. Nature, 2005, 438(7068):685-689.